Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
-$47.84M+17.8%-$50.22M+17.2%-$60.78M-40.9%-$63.42M-75.5%-$58.21M-45.7%
$2.34M+41.9%$2.19M+48.4%$2.17M+75.1%$1.9M+43.7%$1.65M+13.2%
$2.36M+30.6%$2.22M+26.6%$2M+14.9%$1.93M+1.6%$1.81M-22.9%
-$23.98M-5.7%-$22.18M-7.2%-$21.99M-11.3%-$23.02M-27.9%-$22.7M-20.4%
$3.49M+337%$3.19M+517%$1.92M+239%$957K$799K
-$3.49M-339%-$3.19M-522%-$1.92M-$953K-$795K
$49.24M
-$27.48M-16.9%-$25.37M-19.6%-$23.91M-17.6%-$23.98M-$23.5M

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Insight Molecular Diagnostics Inc. Common Stock generate?
Insight Molecular Diagnostics Inc. Common Stock (IMDX) generated -$24.0M in operating cash flow over the trailing twelve months.
What is Insight Molecular Diagnostics Inc. Common Stock's free cash flow?
After $3.5M of capital expenditures, Insight Molecular Diagnostics Inc. Common Stock's free cash flow was -$27.5M over the trailing twelve months, down 16.9% year over year.
Where does Insight Molecular Diagnostics Inc. Common Stock's cash flow data come from?
Every line is extracted from Insight Molecular Diagnostics Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.